TipRanks

Notifications

Cryoport Shareholders Back Board, Auditor and Equity Plan

An announcement from CryoPort ( ($CYRX) ) is now available.

At its annual meeting on June 5, 2026, Cryoport, Inc. shareholders elected six directors, including Linda Baddour and CEO Jerrell W. Shelton, to serve until the 2027 meeting, reaffirming the company’s current board leadership. Investors also ratified Deloitte & Touche LLP as the company’s independent auditor for the fiscal year ending December 31, 2026, signaling continuity in its financial oversight.

Shareholders approved on an advisory basis the compensation of Cryoport’s named executive officers, indicating broad support for the company’s executive pay practices. They further endorsed an amendment to the 2018 Omnibus Equity Incentive Plan to increase the number of authorized shares, enhancing Cryoport’s flexibility to use equity-based awards to attract and retain key talent and potentially align management incentives with long-term shareholder interests.

The most recent analyst rating on ($CYRX) stock is a Hold
with a $13.00 price target.
To see the full list of analyst forecasts on CryoPort stock,
see the CYRX Stock Forecast page.

Spark’s Take on CYRX Stock

According to Spark, TipRanks’ AI Analyst, CYRX is a Neutral.

The score is held back mainly by weak cash flow (negative operating and free cash flow) and still-negative core operating profitability despite positive reported net income. Technicals are supportive with a clear uptrend, but overbought readings add near-term risk. The earnings call was a meaningful positive (raised revenue guidance and improving EBITDA trajectory), while valuation remains challenging due to the negative P/E and no indicated dividend yield.

To see Spark’s full report on CYRX stock,
click here.

More about CryoPort

Cryoport, Inc. operates in the life sciences logistics and biopharmaceutical services industry, providing temperature-controlled supply chain solutions that support the storage and transportation needs of cell and gene therapies, biologics, and other temperature-sensitive materials for pharmaceutical and biotechnology clients.

Average Trading Volume: 659,129

Technical Sentiment Signal: Hold

Current Market Cap: $780.2M

For a thorough assessment of CYRX stock, go to TipRanks’ Stock Analysis page.

Avatar photo
Tipranks Auto-Generated Newsdesk is driven by TipRanks’ Financial Accountability Engine, which brings transparency and accountability to the financial markets. We level the playing field for retail investors, delivering all the news that publicly traded companies release. Our advanced AI scans company announcements, translating complex ideas into easily understandable articles, then sends the articles for editorial review. For any questions or comments, please write to [email protected].